Literature DB >> 14499429

Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C.

Jill C Fehrenbacher1, Charles P Taylor, Michael R Vasko.   

Abstract

Gabapentin and pregabalin are amino acid derivatives of gamma-amino butyric acid that have anticonvulsant, analgesic, and anxiolytic-like properties in animal models. The mechanisms of these effects, however, are not well understood. To ascertain whether these drugs have effects on sensory neurons, we studied their actions on capsaicin-evoked release of the sensory neuropeptides, substance P and calcitonin gene-related peptide from rat spinal cord slices in vitro. Although release of immunoreactive peptides from non-inflamed animals was not altered by either drug, prior in vivo treatment by intraplantar injection of complete Freund's adjuvant enhanced release from spinal tissues in vitro, which was attenuated by gabapentin and pregabalin. These drugs also reduced release of immunoreactive neuropeptides in spinal tissues pretreated in vitro with the protein kinase C activator, phorbol 12,13-dibutyrate. Our results suggest that gabapentin and pregabalin modulate the release of sensory neuropeptides, but only under conditions corresponding to significant inflammation-induced sensitization of the spinal cord.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14499429     DOI: 10.1016/s0304-3959(03)00173-8

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  79 in total

Review 1.  Targeting voltage-gated calcium channels: developments in peptide and small-molecule inhibitors for the treatment of neuropathic pain.

Authors:  S Vink; P F Alewood
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

2.  The alpha2delta ligand gabapentin inhibits the Rab11-dependent recycling of the calcium channel subunit alpha2delta-2.

Authors:  Alexandra Tran-Van-Minh; Annette C Dolphin
Journal:  J Neurosci       Date:  2010-09-22       Impact factor: 6.167

3.  The analgesic effect of pregabalin in patients with chronic pain is reflected by changes in pharmaco-EEG spectral indices.

Authors:  Carina Graversen; Søren S Olesen; Anne E Olesen; Kristoffer Steimle; Dario Farina; Oliver H G Wilder-Smith; Stefan A W Bouwense; Harry van Goor; Asbjørn M Drewes
Journal:  Br J Clin Pharmacol       Date:  2012-03       Impact factor: 4.335

4.  New Horizons in the development of antiepileptic drugs: Innovative strategies.

Authors:  Wolfgang Löscher; Dieter Schmidt
Journal:  Epilepsy Res       Date:  2006-06       Impact factor: 3.045

Review 5.  Pregabalin: in the treatment of postherpetic neuralgia.

Authors:  James E Frampton; Rachel H Foster
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  alpha2delta ligand: a new, smart pill for visceral pain in patients with hypersensitive irritable bowel syndrome?

Authors:  Michael Camilleri
Journal:  Gut       Date:  2007-10       Impact factor: 23.059

Review 7.  Pregabalin in the treatment of chronic pain: an overview.

Authors:  S Chiechio; M Zammataro; F Caraci; L Rampello; A Copani; A F Sabato; F Nicoletti
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

8.  The antiallodynic action of pregabalin may depend on the suppression of spinal neuronal hyperexcitability in rats with spared nerve injury.

Authors:  Lei Ding; Jie Cai; Xiang-Yang Guo; Xiu-Li Meng; Guo-Gang Xing
Journal:  Pain Res Manag       Date:  2014-05-21       Impact factor: 3.037

9.  Pregabalin reduces alcohol drinking and relapse to alcohol seeking in the rat.

Authors:  Serena Stopponi; Lorenzo Somaini; Andrea Cippitelli; Giordano de Guglielmo; Marsida Kallupi; Nazzareno Cannella; Gilberto Gerra; Maurizio Massi; Roberto Ciccocioppo
Journal:  Psychopharmacology (Berl)       Date:  2011-09-02       Impact factor: 4.530

10.  Modulation of voltage-gated Ca2+ channels in rat retinal ganglion cells by gabapentin.

Authors:  Spring R Farrell; Allison Sargoy; Nicholas C Brecha; Steven Barnes
Journal:  Vis Neurosci       Date:  2014-01       Impact factor: 3.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.